Biothera Appoints Research SVP

Jeremy R. Graff, Ph.D., has been appointed senior vice president of Research for Biothera’s Pharmaceutical Group. Most recently, Dr. Graff served as a research fellow and group leader, Oncology Patient Tailoring at Eli Lilly and Co.
 
Dr. Graff has extensive experience across drug discovery and development having led numerous programs from target inception through early and late stage clinical development. He led the efforts to establish the therapeutic mechanism of action for numerous early phase clinical assets, most notably the small molecule kinase inhibitor, enzastaurin, in Diffuse Large B Cell Lymphoma and glioblastoma. Most recently, he shared responsibility for developing and leading translational oncology efforts at Lilly.
 
Dr. Graff has published nearly 60 research articles that have garnered more than 14,000 research citations. He currently serves as a senior reviews editor and associate editor for Cancer Research.
 
“Dr. Graff’s career defines excellence in research and we are delighted to welcome him to Biothera,” said Dan Conners, Biothera Pharmaceutical group president. “We believe he will make significant contributions to the mechanistic understanding of our cancer immunotherapeutic, Imprime PGG, which we hope will ultimately benefit patients in the clinic.”